Literature DB >> 24118982

Factor XI anion-binding sites are required for productive interactions with polyphosphate.

Y Geng1, I M Verhamme, S A Smith, Q Cheng, M Sun, J P Sheehan, J H Morrissey, D Gailani.   

Abstract

BACKGROUND: Conversion of factor XI (FXI) to FXIa is enhanced by polymers of inorganic phosphate (polyP). This process requires FXI to bind to polyP. Each FXIa subunit contains anion-binding sites (ABSs) on the apple 3 (A3) and catalytic domains that are required for normal heparin-mediated enhancement of FXIa inhibition by antithrombin. AIMS: To determine the importance of FXI ABSs to polyP enhancement of FXI activation.
METHODS: Recombinant FXI variants lacking one or both ABSs were tested in polyP-dependent purified protein systems, plasma clotting assays, and a murine thrombosis model.
RESULTS: In the presence of polyP, activation rates for FXI lacking either ABS were reduced compared with wild-type FXI, and FXI lacking both sites had an even greater defect. In contrast to heparin, polyP binding to FXIa did not enhance inhibition by antithrombin and did not interfere with FXIa activation of FIX. FXI lacking one or both ABSs does not reconstitute FXI-deficient plasma as well as wild-type FXI when polyP was used to initiate coagulation. In FXI-deficient mice, FXI lacking one or more ABSs was inferior to wild-type FXI in supporting arterial thrombus formation.
CONCLUSIONS: The ABSs on FXIa that are required for expression of heparin's cofactor activity during protease inhibition by antithrombin are also required for expression of polyP cofactor activity during FXI activation. These sites may contribute to FXI-dependent thrombotic processes.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood coagulation; factor XI; factor XIa; heparin; polyPhosphates

Mesh:

Substances:

Year:  2013        PMID: 24118982      PMCID: PMC3865764          DOI: 10.1111/jth.12414

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  34 in total

1.  Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII.

Authors:  B N Bouma; J H Griffin
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.157

2.  Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Linkage of protease-inhibitor-heparin interactions in the reaction with thrombin.

Authors:  S T Olson
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

Review 3.  Inorganic polyphosphate: a molecule of many functions.

Authors:  A Kornberg; N N Rao; D Ault-Riché
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

4.  Neutrophil extracellular traps promote deep vein thrombosis in mice.

Authors:  A Brill; T A Fuchs; A S Savchenko; G M Thomas; K Martinod; S F De Meyer; A A Bhandari; Denisa D Wagner
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

5.  Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation.

Authors:  Stephanie A Smith; Sharon H Choi; Julie N R Collins; Richard J Travers; Brian C Cooley; James H Morrissey
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

6.  Antithrombin action of phosvitin and other phosphate-containing polyanions is mediated by heparin cofactor II.

Authors:  F C Church; C W Pratt; R E Treanor; H C Whinna
Journal:  FEBS Lett       Date:  1988-09-12       Impact factor: 4.124

7.  Nucleic acid scavengers inhibit thrombosis without increasing bleeding.

Authors:  Shashank Jain; George A Pitoc; Eda K Holl; Ying Zhang; Luke Borst; Kam W Leong; Jaewoo Lee; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-25       Impact factor: 11.205

8.  Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes.

Authors:  Felix A Ruiz; Christopher R Lea; Eric Oldfield; Roberto Docampo
Journal:  J Biol Chem       Date:  2004-08-11       Impact factor: 5.157

9.  The dimeric structure of factor XI and zymogen activation.

Authors:  Yipeng Geng; Ingrid M Verhamme; Stephen B Smith; Mao-Fu Sun; Anton Matafonov; Qiufang Cheng; Stephanie A Smith; James H Morrissey; David Gailani
Journal:  Blood       Date:  2013-03-20       Impact factor: 22.113

10.  In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.

Authors:  Y Hojima; C G Cochrane; R C Wiggins; K F Austen; R L Stevens
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

View more
  24 in total

1.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

2.  Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Authors:  Rami A Al-Horani; David Gailani; Umesh R Desai
Journal:  Thromb Res       Date:  2015-04-22       Impact factor: 3.944

Review 3.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

4.  Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.

Authors:  Qiulan Ding; Likui Yang; Xiaoqing Zhao; Wenman Wu; Xuefeng Wang; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2016-12-15       Impact factor: 5.249

5.  Polyphosphate and RNA Differentially Modulate the Contact Pathway of Blood Clotting.

Authors:  Joshua M Gajsiewicz; Stephanie A Smith; James H Morrissey
Journal:  J Biol Chem       Date:  2016-12-22       Impact factor: 5.157

Review 6.  Polyphosphate as modulator of hemostasis, thrombosis, and inflammation.

Authors:  J H Morrissey; S A Smith
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

7.  A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.

Authors:  Rami A Al-Horani; Elsamani I Abdelfadiel; Daniel K Afosah; Shravan Morla; Jyothi C Sistla; Bassem Mohammed; Erika J Martin; Masahiro Sakagami; Donald F Brophy; Umesh R Desai
Journal:  J Thromb Haemost       Date:  2019-09-10       Impact factor: 5.824

Review 8.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

9.  Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Authors:  Ivan Ivanov; Ruhama Shakhawat; Mao-Fu Sun; S Kent Dickeson; Cristina Puy; Owen J T McCarty; Andras Gruber; Anton Matafonov; David Gailani
Journal:  Thromb Haemost       Date:  2017-01-26       Impact factor: 5.249

Review 10.  The hemostatic role of factor XI.

Authors:  Cristina Puy; Rachel A Rigg; Owen J T McCarty
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.